Nuwellis reports Q1 2026 revenue up 26%, gross margin at 70.1%, and advances in pediatric and cardiorenal tech.

Nuwellis, Inc. announced a 26% revenue increase to $2.4 million for Q1 2026, driven by growth in pediatric, adult heart failure, and critical care segments. The company improved its gross margin to 70.1% through better pricing, product mix, and contract manufacturing. Key developments include acquiring Rendiatech to enhance kidney-function monitoring, appointing new executives, expanding sales coverage, and securing patents for pediatric and ultrafiltration technologies. Despite a net loss of $4.3 million, Nuwellis is focusing on commercial execution and growth in cardiorenal solutions.